300966 Hubei Goto Biopharm
- 16.52
- +0.18+1.10%
Hubei Goto Biopharm News
Guotong Pharmaceutical (300966.SZ): The accumulated new borrowing in the year exceeds 20% of the net assets at the end of the previous year.
On July 5th, Gelunhui announced that as of the end of 2023, the company's audited net assets were 1.0237756 billion yuan, and the loan balance was 481.3159 million yuan. As of July 5, 2024, the company's loan balance was 762.3485 million yuan (unaudited), an increase of 281.0326 million yuan from the end of 2023, and the accumulated new borrowing in 2024 accounted for 27.45% of the net assets at the end of 2023.
Jointown Pharmaceutical Group (SZSE: 300966) plans to distribute a cash dividend of 0.16 yuan per share on June 12.
Common Pharm (300966.SZ) announced that the equity distribution plan for 2023 is as follows: 0.16 yuan per 10 shares...
Kyodo Pharmaceutical (300966.SZ): Net profit of 3,5473 million yuan in the first quarter decreased by 11.86% year on year
On April 25, Ge Longhui (300966.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 122 million yuan, up 2.35% year on year; net profit attributable to shareholders of listed companies was 3.5473 million yuan, down 11.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 3.4646 million yuan, up 2,911.68% year on year; basic earnings per share were 0.03 yuan.
Pacific Securities: The API industry is in the de-inventory phase or nearing its end, and the 24-year sector is expected to usher in a beta market
The Zhitong Finance App learned that Pacific Securities released a research report saying that in December 2023, production of chemical raw materials by industrial enterprises above the Chinese scale began to resume growth, with a year-on-year increase of 2% and a month-on-month increase of 35%. From January to February 2024, production was 546,000 tons. Although the year-on-year decline was 7.6%, it has already exceeded the same period in 2021 and 2022, continuing the improvement at the end of 2023. As major product patents expire one after another and overseas inventory removal gradually comes to an end, the demand side of the API sector is expected to gradually pick up in 2024, ushering in a beta market. Recommended attention: 1) Continued direction in 2024
Zhitong A Share Sale Restriction and Release List | April 9
According to the Zhitong Finance App, the ban on restricted shares of 7 listed companies was lifted on April 9, with a total market value of about 5.471 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, number of shares unbanned, Huabei Pharmaceutical 600812 issued additional A shares, the original shareholder placed 84.256 million shares before issuance, limited sale and circulation 102 million, Jinyu Medical 603882, the original shareholders placed 3.1237 million additional A shares, the original shareholder placed and listed 3.1237 million Yingqu Technology 002925 share incentives to limit circulation 254,200 CCC Radiation 300962 shares restricted circulation before issuance 1.4
Kyodo Pharmaceutical (300966.SZ): The ban on 43.4691 million shares issued before the initial launch will be lifted on April 9
On April 3, Ge Longhui (300966.SZ) announced an indicative announcement on the listing and circulation of shares issued before the initial public offering. A total of 3 shareholders have lifted the sales restrictions. The number of restricted shares lifted is 43.4691 million shares, accounting for 37.71% of the company's total share capital; the listing and circulation date of the shares that have been lifted is April 9, 2024 (Tuesday).
Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Kyodo Pharmaceutical (300966.SZ) grants 150,500 restricted shares at a grant price of 14.67 yuan/share
Kyodo Pharmaceutical (300966.SZ) announced that the company's board of directors and supervisors reviewed and approved “On Approving Incentive Targets...
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Kyodo Pharmaceutical (300966.SZ): Recently received a total of 116.16 million yuan in government subsidies
Gelonghui, January 31 | Kyodo Pharmaceutical (300966.SZ) announced that the company and its wholly-owned subsidiary Hubei Kyodo Biotechnology Co., Ltd. (“Kyodo Bio”) recently received asset-related government grants totaling RMB 116.16 million, accounting for 28.90% of the company's most recent audited net profit.
Kyodo Pharmaceutical (300966.SZ): Plans to establish a holding subsidiary in the US
On January 25, Gelonghui | Kyodo Pharmaceutical (300966.SZ) announced that based on the company's business development needs and considerations of the company's international strategic layout, in order to better explore the American market and serve overseas customers, the company plans to establish a holding subsidiary AURORALLC in the US.
Kyodo Pharmaceutical (300966.SZ): Currently, the construction of the fund-raising project is in the final stage, and trial production will begin before the end of the year
On November 12, Gelonghui (300966.SZ) said in response to a survey of specific targets that the current fund-raising project construction is in the final stage, and trial production will begin before the end of the year; it is expected that the production capacity of the fund-raising project will be released by 40%-50% in 2024, 70%-80% in 2025, and more than 90% of production capacity in 2026.
Kyodo Pharmaceutical (300966.SZ): The performance of the fourth quarter will improve compared to the third quarter
On November 12, Gelonghui (300966.SZ) said in response to a survey of specific targets that the company's overall marketing was carried out in accordance with the sales plan drawn up at the beginning of the year, and its performance in the fourth quarter would improve compared to the third quarter.
Kyodo Pharmaceutical (300966.SZ): The price inflection point in the steroid industry is expected to occur in the first half of 2024
On November 12, Gelonghui (300966.SZ) said in response to a survey of specific targets that according to current market conditions and industry price rules, the price inflection point is expected to occur in the first half of 2024.
Kyodo Pharmaceutical (300966.SZ): Net profit of 22.78 million yuan in the first three quarters fell 42.92% year-on-year
Glonghui, Oct. 24, 丨 Kyodo Pharmaceutical (300966.SZ) announced its third quarter report. Revenue was 385 million yuan, down 13.83% year on year, net profit was 22.78 million yuan, down 42.92% year on year, after deducting non-net profit of 16.247 million yuan, down 55.26% year on year, and basic earnings per share were 0.20 yuan.
Kyodo Pharmaceutical (300966.SZ) announced semi-annual results, net profit of 17.47 million yuan, a year-on-year decrease of 35.24%
Kyodo Pharmaceutical (300966.SZ) disclosed the 2023 semi-annual report. The company achieved revenue of 2.68 during the reporting period...
Does The Market Have A Low Tolerance For Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Mixed Fundamentals?
Kyodo Pharmaceutical (300966.SZ): The actual controllers are Zu Bin and Chen Wenjing, who have transferred a total of 439,600 “joint debt transfers”
GLONGHUI, July 12丨Kyodo Pharmaceutical (300966.SZ) announced that recently, the company received a notice that the actual controllers were Zu Bin and Chen Wenjing, and learned that between July 3, 2023 and July 12, 2023, it transferred a total of 439,600 “joint transfer bonds” it held through bulk transactions, accounting for 11.57% of the total amount issued.
Is The Market Rewarding Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Hubei Goto BiopharmLtd (SZSE:300966) Stock Falls 11% in Past Week as One-year Earnings and Shareholder Returns Continue Downward Trend
Analysis
Price Target
No Data
